An arthritis drug may cut deaths in hospitalized COVID-19 patients by about two thirds among those suffering from moderate or severe cases of the virus, according to a new study.
Called baricitinib, and marketed under the brand name Olumiant, the medication has been touted by its British company as a possible game changer in the fight against COVID-19, the Daily Mail reported.
The rheumatoid arthritis drug, which has been available for only three years, was identified in February as a strong candidate to help treat what was then the emerging threat of the novel coronavirus, according to the outlet.
London-based BenevolentAI examined thousands of existing drugs for signs they might be effective against the deadly bug. The company’s artificial intelligence program predicted that the arthritis drug would “reduce the ability of the virus to infect lung cells,” the Daily Mail reported.
And now, a study by European researchers and led by Sweden’s Karolinska Institute found that baricitinib dramatically cut